0
Signin
countryflagUS

18889881171

AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%

SIGA Technologies Inc

Healthcare US SIGA

8.64USD
-0.02(0.23%)

Last update at 2024-04-25T20:00:00Z

Day Range

8.498.70
LowHigh

52 Week Range

4.217.84
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 44.13M 89.31M 73.51M -10.17842M 411.64M
Minority interest - - - - -
Net income 33.90M 69.45M 56.34M -7.24115M 421.81M
Selling general administrative 35.12M 17.32M 14.00M 13.25M 12.88M
Selling and marketing expenses - - - - -
Gross profit 77.82M 107.13M 99.22M 11.66M 368.77M
Reconciled depreciation 0.52M 0.52M 0.53M 0.53M 0.07M
Ebit 42.70M 89.09M 84.50M 0.50M 434.04M
Ebitda 43.73M 89.72M 85.56M 1.03M 434.11M
Depreciation and amortization 1.03M 0.62M 1.06M 0.53M 0.07M
Non operating income net other 1.43M 0.22M -7.97522M 2.82M 78.94M
Operating income 42.70M 89.09M 84.50M 0.50M 355.10M
Other operating expenses 68.08M 44.58M 40.46M 29.06M 121.95M
Interest expense -0.91831M 0.12M 3.02M 15.77M 15.48M
Tax provision 10.23M 19.86M 17.17M -2.93728M -10.16827M
Interest income - - - 10.68M 22.40M
Net interest income 0.00000M 0.00000M -3.01682M -15.76977M -15.47820M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 10.23M 19.86M 17.17M -2.93728M -10.16827M
Total revenue 110.78M 133.67M 124.96M 26.74M 477.05M
Total operating expenses 35.12M 18.03M 14.72M 13.98M 13.67M
Cost of revenue 32.96M 26.54M 25.74M 15.09M 108.29M
Total other income expense net 1.43M 0.22M -10.99204M -10.67851M 72.02M
Discontinued operations - - - - -
Net income from continuing ops 33.90M 69.45M 56.34M -7.24115M 421.81M
Net income applicable to common shares 33.90M 69.45M 56.34M -7.24115M 421.81M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 195.04M 214.73M 149.83M 198.57M 203.44M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.32M 2.45M 2.11M 100.97M 4.32M
Total liab 24.88M 40.41M 20.04M 100.78M 100.53M
Total stockholder equity 170.16M 174.31M 129.79M 97.78M 102.91M
Deferred long term liab - - - - -
Other current liab 7.05M 24.23M 5.47M 5.92M 0.90M
Common stock 0.00727M 0.00735M 0.00772M 0.00813M 0.00808M
Capital stock 0.00727M 0.00735M 0.00772M 0.00813M 0.00808M
Retained earnings -63.80499M -51.76326M -95.19288M -123.03241M -115.79126M
Other liab 2.39M 7.79M 7.66M 9.05M 13.64M
Good will 0.90M 0.90M 0.90M 0.90M 0.90M
Other assets 6.50M 214.73M 3.22M 15.01M 81.08M
Cash 98.79M 103.14M 117.89M 65.25M 100.65M
Cash and equivalents - - - - -
Total current liabilities 21.52M 30.49M 10.48M 91.74M 11.34M
Current deferred revenue 10.58M 3.76M 3.28M 2.30M 4.16M
Net debt -98.26245M -102.67199M -117.44030M 15.22M -25.10521M
Short term debt 0.53M 0.47M 0.45M 80.46M 4.58M
Short long term debt - - - 80.04M -
Short long term debt total 0.53M 0.47M 0.45M 80.46M 75.55M
Other stockholder equity 233.96M 226.07M 224.98M 220.81M 221.94M
Property plant equipment 1.85M 2.37M 2.10M 2.62M 0.17M
Total current assets 185.79M 208.75M 143.61M 180.04M 121.29M
Long term investments - - - - -
Net tangible assets 170.16M 173.42M 128.89M 96.89M 102.02M
Short term investments - - - - -
Net receivables 45.41M 83.65M 3.34M 4.17M 1.96M
Long term debt - - - - 75.55M
Inventory 39.27M 19.51M 20.27M 9.65M 2.91M
Accounts payable 3.36M 2.03M 1.28M 3.05M 1.69M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - -3.72631M -3.24486M
Additional paid in capital - - - - -
Common stock total equity 0.00727M 0.00735M 0.00772M 0.00813M 0.00808M
Preferred stock total equity - - - - -
Retained earnings total equity -63.80499M -51.76326M -95.19288M -123.03241M -115.79126M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.25M 0.29M 0.68M 0.86M 69.35M
Deferred long term asset charges - - - 14.15M 11.73M
Non current assets total 9.25M 5.97M 6.22M 18.52M 82.15M
Capital lease obligations 0.53M 0.47M 0.45M 0.42M -
Long term debt total - - - - 75.55M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.00000M -0.05062M -0.01550M -0.02909M 78.24M
Change to liabilities -9.01485M 19.76M -1.22178M -0.92477M 5.52M
Total cashflows from investing activities - -0.05062M -0.01550M -0.02909M 78.24M
Net borrowings - - -85.91346M -85.91346M -85.91346M
Total cash from financing activities -45.95926M -26.19544M -114.60042M -1.17658M -3.81256M
Change to operating activities 0.17M 0.05M 0.70M -0.71427M -2.57933M
Net income 33.90M 69.45M 56.34M -7.24115M 421.81M
Change in cash -4.34820M -14.75142M -43.09669M -19.40998M 143.30M
Begin period cash flow 103.14M 117.89M 160.99M 180.40M 37.10M
End period cash flow 98.79M 103.14M 117.89M 160.99M 180.40M
Total cash from operating activities 41.61M 11.49M 71.52M -18.20430M 68.87M
Issuance of capital stock - - - - 0.00000M
Depreciation 0.52M 0.52M 0.53M 0.53M 0.07M
Other cashflows from investing activities - - - - 78.34M
Dividends paid -32.94040M 32.94M 32.94M 32.94M -
Change to inventory -19.96418M 0.14M -8.00999M -6.74464M 0.00004M
Change to account receivables 38.24M -80.31019M 0.83M -2.20886M -0.04972M
Sale purchase of stock -13.00633M -26.02152M -28.50295M - 0.26M
Other cashflows from financing activities -0.01253M -0.17392M -0.18402M -1.17658M -3.81256M
Change to netincome -2.04847M 1.39M 18.83M -0.30362M -7.02825M
Capital expenditures 0.00000M 0.05M 0.02M 0.03M 0.10M
Change receivables 38.24M -80.31019M 0.83M -2.20886M -0.04972M
Cash flows other operating -0.02738M 0.55M 4.22M -1.30826M -351.44911M
Exchange rate changes - - - - -
Cash and cash equivalents changes -4.34820M -14.75142M -43.09669M -19.40998M 143.30M
Change in working capital 9.44M -60.36675M -7.70493M -10.59254M 2.89M
Stock based compensation 1.78M 1.27M 1.35M 2.11M 2.27M
Other non cash items -0.19919M 0.50M 9.39M -0.59398M -348.86978M
Free cash flow 41.61M 11.44M 71.50M -18.23340M 68.77M

Fundamentals

  • Previous Close 8.66
  • Market Cap394.20M
  • Volume381096
  • P/E Ratio-
  • Dividend Yield8.06%
  • EBITDA-9.32871M
  • Revenue TTM34.79M
  • Revenue Per Share TTM0.48
  • Gross Profit TTM 77.82M
  • Diluted EPS TTM-0.08

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SIGA
SIGA Technologies Inc		 -0.02 0.23% 8.64 - 4.91 11.44 3.23 9.50 -41.8429
ZTS
Zoetis Inc		 2.48 1.64% 153.36 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.37 1.14% 32.07 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 6.97 4.40% 165.33 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.16 1.21% 13.07 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

SIGA Technologies Inc

31 East 62nd Street, New York, NY, United States, 10065

Key Executives

Name Title Year Born
Dr. Phillip Louis Gomez III, M.D., Ph.D. CEO & Director 1967
Mr. Daniel J. Luckshire Exec. VP, CFO & Sec. 1971
Dr. Dennis E. Hruby Exec. VP & Chief Scientific Officer 1952
Ms. Tove C. Bolken Sr. VP of Operations & Chief Supply Chain Officer NA
Mr. Herb Vloedman Sr. VP & Chief Information Officer NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).